Sevinc Alper, Camci Celalettin, Buyukberber Suleyman, Akgul Bulent
Department of Medical Oncology, School of Medicine, Gaziantep University, Gaziantep Oncology Hospital, Gaziantep 27310, Turkey.
Med Oncol. 2007;24(3):357-9. doi: 10.1007/s12032-007-0005-0.
Although generally well tolerated there have been a number of reports of acute deterioration in renal function with the use of intravenous immune globulin (IVIG). It is of generally limited duration and is self-limiting. We for the first time have described a patient with multiple myeloma and normal renal function who developed chronic renal failure shortly after IVIG treatment in a patient with no pre-existing renal disease. We would therefore recommend the cautious use of IVIG in patients with normal renal function or with pre-existing renal disease. Renal function should also be assessed both prior to and after application of IVIG.
尽管静脉注射免疫球蛋白(IVIG)通常耐受性良好,但仍有一些关于使用该药物后肾功能急性恶化的报告。这种情况通常持续时间有限且具有自限性。我们首次描述了一名患有多发性骨髓瘤且肾功能正常的患者,在没有既往肾脏疾病的情况下,接受IVIG治疗后不久就发展为慢性肾衰竭。因此,我们建议在肾功能正常或有既往肾脏疾病的患者中谨慎使用IVIG。在应用IVIG之前和之后也应评估肾功能。